Internal restructuring
Location of affected unit(s)
Denmark, China, USA
Professional Services
Scientific, Architectural And Engineering Technical Activities
Scientific Research And Development
72.1 - Research and experimental development on natural sciences and engineering

200 - 400 jobs
Number of planned job losses
Job loss
Announcement Date
2 September 2014
Employment effect (start)
2 September 2014
Foreseen end date
1 June 2015


On 2 September 2014, the Danish pharmaceuticals multinational Novo Nordisk announced that it intended to discontinue all its research and development (R&D) activities within its inflammatory disorders division, affecting a total of 400 jobs in Denmark, China and the USA. In the USA, it will close its inflammation research centre in Seattle, with the loss of 63 jobs.

Novo Nordisk currently estimates that it will be possible to offer other positions within the company to more than half of the 400 affected employees. The company has initiated negotiations with the relevant local unions regarding redundancy plans.


  • 2 September 2014: politiken.dk


Eurofound (2014), Novo Nordisk, Internal restructuring in World, factsheet number 77845, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/77845.